Department of Ophthalmology/UPMC Eye Center, University of Pittsburgh, Pittsburgh, PA, USA.
EMBO Mol Med. 2023 Feb 8;15(2):e17259. doi: 10.15252/emmm.202217259. Epub 2023 Jan 30.
Ocular and specifically retinal toxicities of systemic medications are prevalent and encompass many disease modalities. For many of these pharmaceuticals, established follow-up protocols are in place to ensure timely detection and cessation of therapy. However, while for some disorders, cessation of therapy is a viable option due to existing treatment alternatives, for some others cessation of treatment can be life threatening and/or shorten the patient's life expectancy. Such is the case for iron chelating agents used in transfusion-dependent patients of Thalassemia, of which deferoxamine (DFO) is the most widely used. In their recent article in EMBO Molecular Medicine, Kong et al (2023) addressed the issue of DFO-induced retinal toxicity used both in vivo and in vitro techniques. Their study suggests a potentially protective role for α-ketoglutarate (AKG) supplementation against DFO toxicity.
全身药物引起的眼部，特别是视网膜毒性很常见，涉及多种疾病模式。对于许多这些药物，已经制定了既定的随访方案以确保及时发现并停止治疗。然而，虽然对于某些疾病，由于存在其他治疗选择，停止治疗是可行的，但对于其他一些疾病，停止治疗可能会危及生命和/或缩短患者的预期寿命。对于依赖输血的地中海贫血症患者使用的铁螯合剂就是这种情况，其中最广泛使用的是去铁胺 (DFO)。在他们最近发表在 EMBO Molecular Medicine 上的文章中，Kong 等人 (2023) 使用体内和体外技术解决了 DFO 诱导的视网膜毒性问题。他们的研究表明，α-酮戊二酸 (AKG) 补充可能对 DFO 毒性具有潜在的保护作用。
